- Advanced search
|Approved drug?||Yes (source: FDA and EMA (2010))|
|International Nonproprietary Names|
|Search PubMed clinical trials||denosumab|
|Search PubMed titles||denosumab|
|Search PubMed titles/abstracts||denosumab|
|Denosumab suppresses the activity of RANK ligand (RANKL), which normally promotes bone removal and resorption, but which becomes over active in many bone loss diseases.
Denosumab is produced from CHO cells stably expressing recombinant antibody component proteins .